These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Bevacizumab in glioblastoma--still much to learn. Fine HA N Engl J Med; 2014 Feb; 370(8):764-5. PubMed ID: 24552324 [No Abstract] [Full Text] [Related]
4. Neuro-oncology: Bevacizumab prolongs progression-free survival but not overall survival in newly diagnosed glioblastoma. Malkki H Nat Rev Neurol; 2014 Apr; 10(4):179. PubMed ID: 24638136 [No Abstract] [Full Text] [Related]
6. Neuro-oncology: What is the optimal use of bevacizumab in glioblastoma? Desjardins A Nat Rev Neurol; 2015 Aug; 11(8):429-30. PubMed ID: 26195258 [No Abstract] [Full Text] [Related]
7. Identification of Patients Who Benefit From Bevacizumab in High-Grade Glioma-An Easy Question Turned Difficult: Treat the Scan or the Patient? Kruser TJ; Mehta MP; Kozak KR J Clin Oncol; 2016 Apr; 34(11):1281-2. PubMed ID: 26884565 [No Abstract] [Full Text] [Related]
8. Bevacizumab for glioblastoma multiforme after traumatic subarachnoid hemorrhage. Lukas RV; Goldenberg F; Nicholas MK J Clin Neurosci; 2012 Sep; 19(9):1310-1. PubMed ID: 22721885 [TBL] [Abstract][Full Text] [Related]
14. Questions regarding the optimal use of bevacizumab in glioblastoma: a moving target. Stupp R; Weller M Neuro Oncol; 2014 Jun; 16(6):765-7. PubMed ID: 24826844 [No Abstract] [Full Text] [Related]
15. Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma. Hainsworth JD; Shih KC; Shepard GC; Tillinghast GW; Brinker BT; Spigel DR Clin Adv Hematol Oncol; 2012 Apr; 10(4):240-6. PubMed ID: 22706484 [TBL] [Abstract][Full Text] [Related]
16. Can We Predict Bevacizumab Responders in Patients With Glioblastoma? Mayer TM J Clin Oncol; 2015 Sep; 33(25):2721-2. PubMed ID: 26195699 [No Abstract] [Full Text] [Related]
18. [Survival benefit from the addition of bevacizumab to first-line radiochemotherapy for the treatment of proneural glioblastoma?]. Seidel C; Kortmann RD Strahlenther Onkol; 2016 Jan; 192(1):65-6. PubMed ID: 26560703 [No Abstract] [Full Text] [Related]
19. Predicting glioblastoma response to bevacizumab through marker profiling? Kessler T Neuro Oncol; 2016 Feb; 18(2):149-50. PubMed ID: 26803809 [No Abstract] [Full Text] [Related]
20. Bevacizumab and glioblastoma: scientific review, newly reported updates, and ongoing controversies. Field KM; Jordan JT; Wen PY; Rosenthal MA; Reardon DA Cancer; 2015 Apr; 121(7):997-1007. PubMed ID: 25263092 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]